Amended Current Report Filing (8-k/a)
31 Luglio 2020 - 11:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A-2
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
July 31, 2020 (August 1, 2013)
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its
charter)
|
Nevada
|
|
001-15697
|
|
22-3542636
|
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
165
Ludlow Avenue, Northvale, New Jersey 07647
(Address
of principal executive offices)
(201)
750-2646
(Registrant’s
telephone number, including area code)
|
|
|
(Former name or former
address, if changed since last report.)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
|
Trading
Symbol
|
|
Name
of each exchange on which registered
|
|
Common Stock,
par value $0.001 per share
|
|
ELTP
|
|
OTCQB
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
EXPLANATORY NOTE
This Amendment No. 2
to the Current Report on Form 8-K (the “Form 8-K”), originally filed by Elite Pharmaceuticals, Inc. with the Securities
and Exchange Commission (the “Commission”) on August 5, 2013, and amended by Amendment No. 1 which was filed with the
Commission on August 30, 2018, is being filed solely for the purposes of replacing Exhibit 10.1 with a new agreement that contains
no redactions.
Except as described above,
No other changes have been made to the Form 8-K or amendment No. 1 thereto. This Amendment No. 2 does not otherwise amend, change,
modify or update the disclosures set forth in the Form 8-K as originally filed and does not otherwise reflect events, results or
developments that may have occurred, or facts that have become known, after the original filing of the Form 8-K. Accordingly, this
Amendment No. 2 consists only of the cover page, this Explanatory Note, Item 901 of the Form 8-K and the Signature Page.
Item 9.01 Financial
Statements and Exhibits.
(d) The following exhibits are filed with this Current Report:
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this amendment no. 2 to the report on Form 8-K to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Dated: July 31, 2020
|
ELITE PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
/s/ Carter Ward
|
|
|
|
Carter Ward, CFO
|
Grafico Azioni Elite Pharmaceuticals (QB) (USOTC:ELTP)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Elite Pharmaceuticals (QB) (USOTC:ELTP)
Storico
Da Nov 2023 a Nov 2024
